<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383032</url>
  </required_header>
  <id_info>
    <org_study_id>CPHS # 16429</org_study_id>
    <nct_id>NCT00383032</nct_id>
  </id_info>
  <brief_title>Mifepristone Versus Laminaria for Cervical Ripening in Midtrimester Induction</brief_title>
  <official_title>Randomized Controlled Trial of Mifepristone Versus Laminaria for Cervical Ripening In Midtrimester Induction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <brief_summary>
    <textblock>
      Data from other countries have suggested that oral mifepristone used as a cervical ripening&#xD;
      agent may decrease induction to delivery time in midtrimester inductions. To our knowledge,&#xD;
      there are no trials comparing mifepristone to laminaria in a standard clinical setting with&#xD;
      standardized misoprostol induction protocol to examine the issue of induction to delivery&#xD;
      time. We hypothesize that mifepristone will work at least as well as laminaria for&#xD;
      midtrimester cervical ripening prior to induction of labor with misoprostol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <completion_date>June 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>induction to delivery time</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>delivery within 24 hours</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for post-partum D&amp;C</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <enrollment>72</enrollment>
  <condition>Abortion, Induced</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mifepristone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  pregnant women with fetal anomalies, aneuploidy, or demise at 15-22 weeks gestation&#xD;
&#xD;
          -  age greater than 16&#xD;
&#xD;
          -  able to speak English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  prior uterine scar or&#xD;
&#xD;
          -  allergy or history of bad reaction to any of the study drugs or&#xD;
&#xD;
          -  history of chronic adrenal failure or&#xD;
&#xD;
          -  porphyria or&#xD;
&#xD;
          -  concurrent long-term corticosteroid treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen George, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dartmouth-Hitchcock Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>September 28, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2006</study_first_posted>
  <last_update_submitted>December 27, 2007</last_update_submitted>
  <last_update_submitted_qc>December 27, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2008</last_update_posted>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

